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Background: Aryl hydrocarbon receptor interacting protein (AIP) mutations (AIPmut) cause aggressive
pituitary adenomas in young patients, usually in the setting of familial isolated pituitary adenomas.
The prevalence of AIPmut among sporadic pituitary adenoma patients appears to be low; studies have
not addressed prevalence in the most clinically relevant population. Hence, we undertook an
international, multicenter, prospective genetic, and clinical analysis at 21 tertiary referral endocrine
departments.
Methods: We included 163 sporadic pituitary macroadenoma patients irrespective of clinical
phenotype diagnosed at !30 years of age.
Results: Overall, 19/163 (11.7%) patients had germline AIPmut; a further nine patients had sequence
changes of uncertain significance or polymorphisms. AIPmut were identified in 8/39 (20.5%) pediatric
patients. Ten AIPmut were identified in 11/83 (13.3%) sporadic somatotropinoma patients, in 7/61
(11.5%) prolactinoma patients, and in 1/16 non-functioning pituitary adenoma patients. Large
genetic deletions were not seen using multiplex ligation-dependent probe amplification. Familial
screening was possible in the relatives of seven patients with AIPmut and carriers were found in six of
the seven families. In total, pituitary adenomas were diagnosed in 2/21 AIPmut-screened carriers; both
had asymptomatic microadenomas.
Conclusion: Germline AIPmut occur in 11.7% of patients !30 years with sporadic pituitary
macroadenomas and in 20.5% of pediatric patients. AIPmut mutation testing in this population should
be considered in order to optimize clinical genetic investigation and management.
European Journal of Endocrinology 165 509–515ndocrinology DOI: 10.1530/EJE-11-0304
Online version via www.eje-online.org
AUTHOR COPY ONLY
510 M A Tichomirowa, A Barlier, A F Daly and others EUROPEAN JOURNAL OF ENDOCRINOLOGY (2011) 165Introduction
Clinically relevant pituitary adenomas have a prevalence
of one case per 1064–1239 of the population in Western
Europe and an incidence of four cases per 100 000 (1–3).
The majority of pituitary adenomas occur sporadically,
while up to 5% of all cases occur against an inherited or
familial background; more than half are due to multiple
endocrine neoplasia type 1 (MEN1) (4). Familial isolated
pituitary adenomas (FIPA) account for most of the
remaining cases, along with rare conditions such as
Carney’s complex (CNC) or MEN4 (5, 6). Aryl hydro-
carbon receptor interacting protein (AIP) mutations
(AIPmut) occur in 15–30% of FIPA kindreds (7–9). In a
recent large international study of AIPmut-associated
pituitary adenomas, Daly et al. (10) observed that
AIPmut are associated with all types of pituitary
adenomas; these tumors are large, occur at a young
age, and demonstrate features of aggressiveness and
treatment resistance. While somatotropinomas and
prolactinomas predominate, other pituitary adenoma
subtypes do occur in the setting of AIPmut, including
Cushing disease and thyrotropinoma, and the silent
somatotrope subtype of non-functioning adenomas has
also recently been described (10, 11).
AIPmut occur infrequently in unselected populations
of patients with sporadic pituitary tumors (0–3.0%),
in children with sporadic pituitary adenomas (2.7%)
or Cushing disease (1.4%) or in specific sporadic tumor
types (e.g. acromegaly patients: 3.2%) (12–19). This
suggests that AIPmut screening of large, unselected
sporadic pituitary adenoma populations is impractical;
similarly, limited screening performed only in children
could miss cases that develop in patients in their late
teens and twenties (10). In the largest study of pituitary
adenoma patients with AIPmut (nZ96), the most
clearly defined features at diagnosis were macroade-
noma (93.3%) and young age at diagnosis (median:
23.0 years) (10). Combining this information, 81.2%
of patients were diagnosed with a macroadenoma at
!30 years of age. No study to date has used this
existing knowledge on patient/tumor characteristics to
determine whether focused AIPmut screening may be
clinically informative. In order to explore the utility
of focused genetic screening, we investigated the
frequency of AIPmut among patients with sporadic
pituitary macroadenomas that occurred before the
age of 30 years, in whom no other known genetic
cause or FIPA was present.Methods
Patients
This genetic screening study was performed in sporadic
pituitary adenoma patients with tumors R10 mm in
maximal diameter on magnetic resonance imaging (MRI)
that were diagnosed before the age of 30 years. Patientswww.eje-online.orghad to be free of known diagnosis of genetic causes or
familial pituitary adenomas (e.g. MEN1, CNC, MEN4,
McCune–Albright syndrome, or FIPA). The study was
conducted in centers in Belgium, Brazil, Bulgaria, Czech
Republic, France, Germany, Italy, Lebanon, and Spain.
A total of 163 patients provided informed consent in
their own local language to undergo AIP gene
sequencing (72.0% of patients meeting the criteria at
the study centers agreed to undergo genetic testing). In
cases where an AIPmut was found, genetic counseling
and testing were offered to family members. After
counseling, consenting AIPmut carriers underwent
MRI and hormonal testing to assess for the presence
of pituitary disease. Basic demographic, clinical, and
therapeutic response data were collected for patients
with AIPmut. All subjects gave their written informed
consent for themselves or for their minor children, while
assent of the child was also obtained if they were
between 11 and 17 years (no child was under the age of
11 years at the time of genetic testing) and the study
was approved by local ethics committees and the Ethics
Committee of the University of Lie`ge.Genetic analysis
DNA extracted from peripheral blood was analyzed for
AIPmut by direct sequencing. In patients with normal
AIP sequencing, multiplex ligation-dependent probe
amplification (MLPA) was used to search for extensive
deletions, as described previously (12). The control DNA
from 200 healthy individuals included 30 healthy
controls of North African origin to cover this previously
unaddressed population, which was represented in our
European sample.
The potential effect of each intronic or silent variation
on AIP protein was evaluated in silico using a battery of
different tools. For the in silico analyses, a 180–240 base
portion of the AIP gene sequence surrounding each of
the nucleotide variants was evaluated for potential
splicing and/or functional effects using the following
bioinformatic tools: Human Splicing Finder (http://
www.umd.be/HSF/HSF.html), FANS (http://fans.ngc.
sinica.edu.tw/fans/input.do), and FastSNP (http://
fastsnp.ibms.sinica.edu.tw). These tools generate pre-
dictions based on algorithms that compare consensus
sequences for certain motifs (e.g. sites for intronic and
exonic silencers and enhancers) within sequences of
interest. As individual tools provide only an estimation
of potential effect, it is generally recommended that
more than one tool be used to evaluate genomic
variations of interest (20). PolyPhen2 (http://genetics.
bwh.harvard.edu/pph2/index.shtml) was used to evalu-
ate the potential effects of missense mutations on AIP
structure. AIP sequence variants were compared with
human single nucleotide polymorphism (SNP) data-
bases (dbSNP, http://www.ncbi.nlm.nih.gov/SNP/
snp_summary.cgi) and also against recently published
results in genetically diverse populations (21).
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Patient characteristics
A total of 163 patients with sporadic pituitary
macroadenomas diagnosed before the age of 30 years
were included. Eighty-three (50.9%) patients had
somatotropinomas (46 females; mean GS.D. age at
diagnosis: 23G6.2 years, mean GS.D. tumor diameter
29.2G14.7 mm); 61 (37.4%) had prolactinomas
(39 males; mean GS.D. age at diagnosis: 19.6G4.6
years, mean GS.D. tumor diameter 34.5G15.8 mm);
16 (9.8%) had non-functioning pituitary adenomas
(NFPA; nine females; mean GS.D. age at diagnosis:
22.3G5.1 years, mean GS.D. tumor diameter 29.5
G16 mm); two (1.2%) had Cushing disease (both
female, ages at diagnosis: 30.0 and 12.0 years; tumor
diameter 12.0 mm in both); and one patient had a
thyrotropinoma (male, 15.0 years at diagnosis, tumor
diameter 32 mm). Two patients had concomitant brain
tumors, one somatotropinoma patient had a glioblas-
toma of which he later died, and a prolactinoma patient
had a meningioma.AIP sequencing
AIP sequence variations were observed in 28/163
patients (17.2%), of which 19 (11.7%) would likely
result in altered AIP expression or function (Table 1).
MLPA did not reveal any large deletions. The c.100K
18COT change in one patient is a previously reported
rare SNP (rs117691341).
Ten AIPmut were identified in 11/83 (13.3%)
sporadic somatotropinoma patients. Eight patients
were males and seven presented with invasive
tumors. Six of the ten AIPmut led to premature stop
codons (p.Arg22X, p.Glu82fsX7, p.Gly117AlafsX39,
p.Gln184X, p.Tyr261X, and p.Arg304X (nZ2 unre-
lated patients)). The previously described p.Arg271Trp
mutation occurs at an amino acid with an established
structure–function relationship (8, 10, 22, 23). Two
other missense mutations were observed in silico to
have a highly probable effect on protein structure
(p.Glu84Lys and p.Ala277Pro). In silico analyses also
strongly supported a pathological role for the synon-
ymous p.Glu197Glu variant, via alternative splicing at
a splicing enhancer site within an important structural
domain. A c.993C60GOC variant in the 3 0-untrans-
lated region (UTR) had no predicted effect on splicing,
but in silico analyses predicted a new transcription
factor-binding site, resulting in a low-to-medium
likelihood of a deleterious effect. The c.468C16COT
variant predicted a new intronic branch site and also
the generation of a new transcription factor-binding site
in silico, but of a low-to-moderate likelihood of a
deleterious effect. The p.Arg16His variant in one patient
has previously been reported (8, 15), but recently, it was
noted clearly not to segregate with pituitary adenomasin a FIPA kindred (24). Other AIP sequence variants had
no predicted effect on AIP structure/function
(p.Arg128His, c.468C15GOT, and c.993C63COT).
AIPmut were found in 7/61 (11.5%) sporadic
prolactinoma patients, six of whom were males. One
frameshift/truncation (p.Gly117AlafsX39) was patho-
genic. Based on in silico analyses, four missense
mutations predicted deleterious effects (high likelihood:
p.Arg56Cys, p.Lys58Asn, and p.Tyr268Cys; moderate
likelihood: p.Val195Ala). One synonymous change
(p.Phe269Phe) was also deleterious as characterized
by Igreja et al. (9). The p.Arg304Gln AIP variant did not
strongly predict a deleterious effect on the protein
in silico, but previous characterization in vitro suggests
that it is indeed a mutation (9). The p.Arg16His variant
was found in one patient (see above).
One AIPmut (c.88_89delGA and p.Asp30Trpfs14X)
was found in 1/16 (6.25%) NFPA patients. No AIP
variants were seen in the Cushing disease or thyro-
tropinoma patients.Familial screening
Familial screening studies were possible in the relatives
of seven patients with AIPmut. Mutation carriers
were found in six of the seven families. In the family
where no mutation carrier was identified, the asympto-
matic mother of a somatotropinoma patient with a
p.Gly82fsX7 AIPmut declined genetic analysis. Among
a total of 21 AIPmut carriers, MRI revealed undiagnosed
pituitary adenomas in two members of one family with
a p.Arg304X mutation. In that family, three mutation
carriers were identified and the patient’s mother and
sister had pituitary microadenomas, neither of which
was associated with pituitary hormonal abnormalities.AIPmut in pediatric patients with pituitary
adenomas
Considering only pediatric patients (i.e. under the age of
18 years), AIP variations were identified in ten of 39
patients (25.6%) diagnosed before 18 years of age (five
somatotropinomas and four prolactinomas). Eight
variations were likely to be pathogenic in this pediatric
cohort (20.5%), which was a significantly higher rate
than in the patients agedR18 years (11/124; P!0.01).Therapeutic responses
In terms of responses to therapy, the results obtained are
in line with those reported elsewhere in AIPmut-bearing
patients with pituitary adenomas (10). In patients with
somatotropinomas, 4/11 (36.4%) underwent two or
more surgical interventions, while secondary (post-
operative) somatostatin analog therapy achieved
disease control in 1/9 (11%) treated patients. Tumor





Table 1 Clinical characteristic of patients with different AIP gene mutations and variants. Pathological AIP gene mutations (AIPmut) are shown in bold, while variations of unlikely




















1 p.Arg22X (12) M 10 GH 6.9 38 Y Y Y N One mutation carrier, no pituitary tumor
IGF1 N/A
2 p.Glu82fsX7 FJ514477.1 M 15 GH 48.6 60 Y Y Y N No other mutation carriera
IGF1 1404
3 p.Glu84Lys GQ403801.1 F 20 GH 14.9 11 N N Y N N
IGF1 556
4 p.Gly117Alafs39X GQ847774.1 M 18 GH N/A 17 N N Y N N
c.350delG IGF1 810
5 p.Gln184X GQ403802.1 M 21 GH 30.0 N/A Y N/A Y N N
IGF1 1231
6 p.Glu197Glu JN561683 F 23 GH 0.5 26 Y Y Y N N
IGF1 660
7 p.Tyr261X GQ403803.1 M 28 GH 77.0 38 N Y Y N N
IGF1 2443




9 p.Ala277Pro (32) M 12 GH 13.6 27 Y Y Y N One mutation carrier, no pituitary tumor
IGF1 530
10 p.Arg304X (7) F 17 GH 9.0 N/A N/A N/A Y Y (17) N
IGF1 905
11 p.Arg304X (7) M 25 GH 5.6 40 Y Y Y Y (17) Three mutation carriers, two non-functioning
pituitary lesionsIGF1 578
12 p.Arg16His (8) F 29 N/A N/A N/A N/A Y Y; minor (9) N
13 p.Arg128His (32) M 27 GH 58.5 20 N N N N N
IGF1909
14 c.468C15COT (15) F 19 GH 54.8 13 N N N N Two other carrier, no tumor
IGF1 535
15 c.468C16GOT (15) F 15 N/A 23 Y Y Y N N
16 c.993C60 GOC (15, 29) F 34b N/A 15 Y Y Y N N
17 c.993C60 GOC (15, 29) M 22 N/A N/A N/A N/A Y N N
18 c.993C63 COT (15, 29) F 27 GH 26.0 25 N Y N N N
IGF 643
Prolactinoma
19 p.Arg56Cys GU969040 M 26 PRL 5242 70 Y Y Y N N
20 p.Lys58Asn GQ847773.1 M 20 PRL O10000 72 Y Y Y N N
21 p.Gly117Alafs39X GQ847774.1 M 16 PRL 2478 N/A N/A N/A Y N N
c.350delG
22 p.Val195Ala (32) M 12 PRL 10560 40 Y Y Y N Five mutation carriers, no pituitary tumor
23 p.Tyr268Cys GQ412196.1 M 28 PRL 6340 85 Y Y Y N Two mutation carriers, no pituitary tumor
24 p.Phe269Phe (9) M 10 PRL 20 000 N/A Y Y Y Y (9) No
25 p.Arg304Gln (15) M 15 PRL 257 27 Y Y Y Y; minor (9) Seven mutation carriers, no pituitary tumor
26 p.Arg16His (8) M 20 PRL 3867 45 Y NA Y Y; minor (9) N
27 c.100K18COT rs117691341 M 15 PRL 459 28 Y Y N N N
Non-secreting adenoma
28 p.Asp30TrpfsX14 GQ847775.1 M 19 Normal 39 Y Y N N N
c.88_89delGA
N/A, not available; AN, Accession number; Ref., reference; Hor., hormone; tum., tumor; ES, extrasellar; del., deleterious.
*Reference of original mutation description.
aMother of affected patient declined genetic screening.






































































AIPmut in young pituitary macroadenoma patients 513EUROPEAN JOURNAL OF ENDOCRINOLOGY (2011) 165measurable in six cases; in one case, there was 60%
tumor shrinkage, and in the remaining cases, there was
no size change (nZ4) or tumor growth (nZ1). Among
patients with prolactinomas, 3/6 of cases that received
cabergoline did not achieve disease control with usual
clinical doses (3–4 mg/week); there were two cases of
resistance to high-dose cabergoline (7 mg/week), and in
one of these cases, secondary resistance occurred after
initial control. Five prolactinoma patients underwent
neurosurgery (three patients had two interventions
each; one required four interventions) and radiotherapy
was used in three patients. The 19-year-old patient
with a non-secreting pituitary adenoma underwent
neurosurgery twice and radiotherapy thereafter; the
tumor was negative for all pituitary hormones on
immunohistochemistry.Discussion
This is the first study to specifically investigate the
prevalence of AIP sequence variations among patients
thought to be at the greatest risk, namely those
diagnosed with pituitary macroadenomas as children
or young adults (!30 years). The finding of AIPmut in
11.7% of the entire cohort and among 20.5% of
patients aged!18 years at diagnosis strongly supports
the contention that screening for AIPmut among young
sporadic patients with macroadenomas may be clini-
cally useful. We noted no large AIP gene deletions using
MLPA, which suggests that such changes occur in a
minority of cases that are negative for AIPmut on
sequencing (9, 12, 25).
These results expand on those obtained in previous
studies performed using different criteria. Studies in
unselected sporadic pituitary adenoma populations
demonstrated a very low rate of AIPmut status (12–
14, 16). Other studies undertook screening that was
restricted to children/adolescents (18, 26), to those with
FIPA (8, 9), to sporadic somatotropinoma patients (7,
14, 15), or were limited to a subset of AIPmut (19, 27).
These studies identified many novel AIPmut mutations
and, along with more recent work (10), have charac-
terized disease features and responses to therapy.
We identified AIPmut in 13.3% of sporadic somato-
tropinoma patients in our targeted cohort, including six
distinct truncating mutations; an Italian acromegalic
patient had a previously reported missense mutation
(p.Arg271Trp) (8, 10, 23) that was shown to abolish
the interaction of AIP with phosphodiesterase 4A5 (17,
22). Two other missense mutations (p.Glu84Lys and
p.Ala277Pro) were predicted in silico to have probably
damaging effects on AIP protein. Also, a new synon-
ymous p.Glu197Glu mutation was strongly predicted to
have a pathological effect via interrupting a splicing
enhancer site. Notably, the frequency of AIPmut among
prolactinoma patients (11.5%) was similar to that of
somatotropinoma patients. AIPmut in prolactinoma
patients were detected mostly in males and wererelatively difficult to treat with dopamine agonists,
which is in line with other recent work (10). As males
with prolactinomas can represent a particularly difficult
group to treat (28), it is possible that AIPmut status may
partially contribute to this poorer disease control,
although specific studies of AIPmut status in large
prolactinoma cohorts are lacking. The silent variation,
p.Phe269Phe, was previously reported as pathogenic by
disrupting splicing enhancer sites, causing a loss of exon
6 in a FIPA family with two somatotropinoma patients
(9). One novel truncating AIPmut (p.Gly117AlafsX39)
occurred in a 16-year-old patient with a prolactinoma
and also in an unrelated 18-year-old unrelated
acromegalic patient. The p.Lys58Asn, p.Arg56Cys,
p.Tyr268Cys, and p.Val195Ala missense mutations
scored as being likely to affect AIP protein on in silico
analysis. A truncating AIPmut was found in 1/16 NFPA
(6.3%) patients and is to our knowledge the first report
of a pathogenic variation in sporadic NFPA. The patient
was aged 19 years and presented with visual field
alteration and panhypopituitarism due to mass effects.
A previous study identified two AIP variations in a
cohort of 55 NFPA patients, but these were found to be
polymorphisms (16). The number of NFPA patients
included in our study is small, due to the relative rarity
of NFPA in younger individuals. No AIPmut were found
in Cushing disease or thyrotropinoma patients, but this
is again attributed to the small sample size. Cortico-
tropinomas are mainly microadenomas and recently,
sporadic Cushing disease in the young has been shown
to be very rarely associated with AIPmut (18).
Thyrotropinomas are very rare tumors in the general
population, and to date, only one case associated with
AIPmut has been reported (10).
Among the AIP variants, a number were non-
pathogenic on in silico analyses (e.g. c.468C15 COT
and c.993C63 COT). With others, the evidence is less
certain or is contradictory. The p.Arg16His variant
occurs in an evolutionary conserved residue and is
predicted to have a deleterious effect on AIP protein on
in silico analysis. In contrast, Igreja et al. (9) reported
only a modest effect of this variant on AIP function in an
in vitro assay. Also arguing strongly against it being a
mutation is the recent publication from Guaraldi &
Salvatori (24) showing that this change did not
segregate uniformly with pituitary adenomas in a
large FIPA kindred. On balance, the evidence currently
suggests that p.Arg16His is most likely a rare
polymorphism. A p.Arg304Gln mutation was observed
in a 15-year-old boy with a prolactinoma whose family
screening revealed another seven mutation carriers. No
carrier had evidence of pituitary tumor, but one carrier
(his mother) was diagnosed with breast cancer and the
other (his maternal aunt) has a history of stomach
cancer. This mutation occurs at a CpG island hotspot and
was previously reported in two families with GH-secreting
adenomas and in two sporadic cases of corticotropinoma
and one acromegaly patient (13, 15, 17). The strongwww.eje-online.org
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experimental data are apparently divergent, with only
modest effects being seen on in vitro AIP functional assays
(9) and low potential for deleterious effects in silico. The
c.993C60GOC variant in the 30-UTR, while it predicts a
low-to-moderate likelihood of a deleterious effect via a
new transcription factor binding site and has been
reported in colorectal cancer (29), was also present in
normal control subjects and is possibly not a pathological
variant. In vitro testing of AIP variants of uncertain nature
using a more expanded range of assays of AIP function
beyond phosphodiesterase 4A5-based constructs may be
useful to confirm or rule out the pathogenicity of
AIP variants.
As AIPmut are most commonly found either in a FIPA
or familial setting (7–10, 18) and as pituitary adenomas
can be diagnosed in asymptomatic AIPmut carriers via
the screening process (30), we performed screening in
families of AIPmut pituitary adenoma patients. The
completeness of this particular data set is less than
optimal for determining penetrance as family members
in only seven of the 18 AIPmut patients consented to
genetic screening. Mutation carriers were found in six
families while in the seventh family the mother of the
patient declined genetic studies. MRI revealed two
microadenomas among the 21 (9.5%) carriers, which
is in keeping with the relatively low disease penetrance
of pituitary adenomas. While the tumors in these two
AIPmut carriers are clinically silent at present, longer
term follow-up is required similar to recent recommen-
dations on incidentaloma surveillance (31). However, it
is too early to determine whether these are AIPmut-
related tumors or incidentalomas and a high clinical
index of suspicion is warranted. Determining true
disease penetrance in the setting of AIPmut requires
studying a large number of kindreds to allow for detailed
surveillance of a sizeable number of mutation carriers
through childhood/adolescence and early adulthood.
In conclusion, screening for germline AIPmut in
patients aged!30 years with pituitary macroadenomas
was positive in 11.7% of cases and in 20.5% of those
aged !18 years. Testing for AIPmut in children and
young adults diagnosed with macroadenomas could be a
useful addition to screening in FIPA kindreds considering
the relatively high incidence of AIPmut in this well-
defined and readily encountered sub-population (33).Declaration of interest
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